CD8A and non-small cell lung carcinoma: Progression-free survival and overall survival were longer in stage III NSCLC patients undergoing chemoradiotherapy when the density of CD8+ cancer-infiltrating lymphocytes in the pre-treated biopsy specimens was higher than that in patients with low CD8+ cancer infiltrating lymphocyte density [142].